Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Corey Cutler, Stephanie J. Lee, Sally Arai, Marcello Rotta, Behyar Zoghi, Aleksandr Lazaryan, Aravind Ramakrishnan, Zachariah DeFilipp, Amandeep Salhotra, Wanxing Chai-Ho, Rohtesh Mehta, Trent Wang, Mukta Arora, Iskra Pusic, Ayman Saad, Nirav N. Shah, Sunil Abhyankar, Carlos Bachier, John Galvin, Annie ImAmelia Langston, Jane Liesveld, Mark Juckett, Aaron Logan, Levanto Schachter, Asif Alavi, Dianna Howard, Harlan W. Waksal, John Ryan, David Eiznhamer, Sanjay K. Aggarwal, Jonathan Ieyoub, Olivier Schueller, Laurie Green, Zhongming Yang, Heidi Krenz, Madan Jagasia, Bruce R. Blazar, Steven Pavletic

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Belumosudil, an investigational oral selective inhibitor of Rho-associated coiled-coil–containing protein kinase 2 (ROCK2), reduces type 17 and follicular T helper cells via downregulation of STAT3 and enhances regulatory T cells via upregulation of STAT5. Belumosudil may effectively treat patients with chronic graft-versus-host disease (cGVHD), a major cause of morbidity and late nonrelapse mortality after an allogeneic hematopoietic cell transplant. This phase 2 randomized multicenter registration study evaluated belumosudil 200 mg daily (n = 66) and 200 mg twice daily (n = 66) in subjects with cGVHD who had received 2 to 5 prior lines of therapy. The primary end point was best overall response rate (ORR). Duration of response (DOR), changes in Lee Symptom Scale score, failure-free survival, corticosteroid dose reductions, and overall survival were also evaluated. Overall median follow-up was 14 months. The best ORR for belumosudil 200 mg daily and 200 mg twice daily was 74% (95% confidence interval [CI], 62-84) and 77% (95% CI, 65-87), respectively, with high response rates observed in all subgroups. All affected organs demonstrated complete responses. The median DOR was 54 weeks; 44% of subjects have remained on therapy for ≥1 year. Symptom reduction with belumosudil 200 mg daily and 200 mg twice daily was reported in 59% and 62% of subjects, respectively. Adverse events (AEs) were consistent with those expected in patients with cGVHD receiving corticosteroids and other immunosuppressants. Sixteen subjects (12%) discontinued belumosudil because of possible drug-related AEs. Belumosudil, a promising therapy for cGVHD, was well tolerated with clinically meaningful responses. This trial was registered at www.clinicaltrials.gov as #NCT03640481.

Original languageEnglish
Pages (from-to)2278-2289
Number of pages12
JournalBlood
Volume138
Issue number22
DOIs
StatePublished - Dec 2 2021

Fingerprint

Dive into the research topics of 'Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study'. Together they form a unique fingerprint.

Cite this